Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
Simply Wall StApr 22 08:01 ET
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects With Elevated Lipoprotein(a)
Yahoo FinanceApr 8 11:48 ET
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Yahoo FinanceMar 16 08:29 ET
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 15 11:56 ET
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Yahoo FinanceFeb 16 02:53 ET
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking
Silence Therapeutics plc (NASDAQ:SLN) shares have continued their recent momentum with a 26% gain in the last month alone. Looking back a bit further, it's encouraging to see the stock is up 72% in
Simply Wall StFeb 3 07:00 ET
Insiders the Biggest Winners as Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Rises to US$736m
Key Insights Significant insider control over Silence Therapeutics implies vested interests in company growth A total of 4 investors have a majority stake in the company with 53% ownership Instit
Simply Wall StJan 19 05:47 ET
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Yahoo FinanceJan 11 12:00 ET
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?
Yahoo FinanceDec 6, 2023 09:55 ET
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 65% But Growth Is Lacking
Silence Therapeutics plc (NASDAQ:SLN) shares have had a really impressive month, gaining 65% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the loss
Simply Wall StNov 27, 2023 05:04 ET
Virpax Pharmaceuticals CEO and Chairman Resigns on Ongoing Litigation
Seeking AlphaNov 17, 2023 07:38 ET
Silence Therapeutics Plc (NASDAQ:SLN) Short Interest Down 17.1% in February
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 14,500 shares, a drop of 17.1%
Financial News LiveMar 14, 2023 14:44 ET
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
Yahoo FinanceMar 6, 2023 04:06 ET
BVF Inc. IL Has $14.89 Million Stock Position in Silence Therapeutics Plc (NASDAQ:SLN)
BVF Inc. IL raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 126.3% in the third quarter, according to the company in its most recent Form 13F filing with the Se
Financial News LiveFeb 28, 2023 11:42 ET
SG Americas Securities LLC Sells 2,500 Shares of Silence Therapeutics Plc (NASDAQ:SLN)
SG Americas Securities LLC lessened its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 2.5% during the 3rd quarter, according to its most recent disclosure with the SEC.
Defense WorldJan 19, 2023 06:31 ET
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Yahoo FinanceJan 4, 2023 13:37 ET
Silence Therapeutics Plc Expected to Earn FY2022 Earnings of ($0.44) Per Share (NASDAQ:SLN)
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) – HC Wainwright issued their FY2022 earnings estimates for shares of Silence Therapeutics in a research report issued to clients and investors on
Financial News LiveDec 8, 2022 07:32 ET
Short Interest in Silence Therapeutics Plc (NASDAQ:SLN) Increases By 24.2%
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 26,700 shares, a growth of 2
kopsourceDec 1, 2022 17:51 ET
Silence Therapeutics plc (NASDAQ:SLN) Sees Significant Increase in Short Interest
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 287,500 shares, a growth of
ETF Daily NewsApr 14, 2022 10:03 ET
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) ther
GlobeNewswireDec 1, 2021 07:06 ET
No Data
No Data